Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts
Mangia, A.; Milligan, S.; Khalili, M.; Fagiuoli, S.; Shafran, S. D.; Carrat, F.; Ouzan, D.; Papatheodoridis, G.; Ramji, A.; Borgia, S. M.; Wedemeyer, H.; Losappio, R.; Perez-Hernandez, F.; Wick, N.; Brown, R. S.; Lampertico, P.; Doucette, K.; Ntalla, I.; Ramroth, H.; Mertens, M.; Vanstraelen, K.; Turnes Vázquez, Juan
Identificadores
Identificadores
Visualización o descarga de ficheros
Visualización o descarga de ficheros
Fecha de publicación
2020Título de revista
LIVER INTERNATIONAL
Tipo de contenido
Journal Article
DeCS
resultado del tratamiento | ribavirina | antivíricos | carbamatos | genotipo | farmacoterapia | humanos | adulto | Hepacivirus | compuestos heterocíclicosMeSH
Heterocyclic Compounds | Drug Therapy | Adult | Humans | Treatment Outcome | Ribavirin | Hepacivirus | Genotype | Carbamates | Antiviral AgentsResumen
BACKGROUND AND AIMS: Achieving sustained virological response (SVR; cure) in hepatitis C patients using a simple regimen is key to making elimination by 2030 possible. In the largest real-world analysis to date, the effectiveness of pangenotypic, panfibrotic, single-tablet, sofosbuvir/velpatasvir (SOF/VEL) once-daily for 12 weeks was assessed in 12 clinical real-world cohorts from various geographical areas, settings and treatment practices. Factors affecting risk of not achieving SVR were assessed. METHODS: Adults treated with SOF/VEL 400/100 mg, without ribavirin, were included. All HCV patients reaching Week 12 or 24 post-treatment were assessed for SVR12/24. Factors associated with not achieving SVR12/24 for virological reasons were evaluated using logistic regression analysis. RESULTS: Overall, 5552 patients were included: 13.3% treatment-experienced; 20.7% compensated cirrhotic; 30.2% genotype 1; 29.5% genotype 2; 32.9% genotype 3; 4.7% genotype 4; 3.7% HIV coinfection; 13.4% current/former intravenous drug use. Of the 5196 patients evaluated for effectiveness, 98.9% achieved SVR12/24. High SVR12/24 rates occurred in all genotypes including genotype 3 (98.3%; 1649/1677) and in those with compensated cirrhosis (97.9; 1055/1078). Only 55 patients did not achieve SVR12/24 due to a virological reason; the only factor statistically significantly associated with an increased risk of not achieving SVR12/24 was compensated cirrhosis (P = .002). Overall, 6% (332/5552) of patients did not achieve SVR12/24 for non-virological reasons (67% lost to follow-up; 26.5% early treatment discontinuation). CONCLUSIONS: In this large cohort, representative of clinical practice, a simple 12-week regimen of SOF/VEL without ribavirin resulted in high SVR12/24 rates in diverse patient populations, even among those with compensated cirrhosis.